pembrolizumab,lenvatinib
merck,eisai
['leap002', 'lenva', 'pembro']
disappointing reaults of leap002 study of pembrolizumab plus lenvatinib is negative. presented at #esmo2022 
A dedicated conference for oncology held under the theme "Access. Educate. Collaborate"